Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 16c
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.93), $0.16 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $9.33 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- UBS Downgrades Converge ICT Solutions Inc (CNVRG:PM) to Neutral
- JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
